Lilly Preps To File A Rival To Lantus, But Safety Remains In Question
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.